scholarly journals The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2

Immunology ◽  
2014 ◽  
Vol 142 (3) ◽  
pp. 474-483 ◽  
Author(s):  
Matthew P. Wood ◽  
Amy L. Cole ◽  
Colleen R. Eade ◽  
Li-Mei Chen ◽  
Karl X. Chai ◽  
...  
Virology ◽  
2002 ◽  
Vol 302 (1) ◽  
pp. 174-184 ◽  
Author(s):  
Ruben M. Markosyan ◽  
Xiuwen Ma ◽  
Min Lu ◽  
Fredric S. Cohen ◽  
Grigory B. Melikyan

2006 ◽  
Vol 360 (1) ◽  
pp. 45-55 ◽  
Author(s):  
Maier Lorizate ◽  
María J. Gómara ◽  
Beatriz G. de la Torre ◽  
David Andreu ◽  
José L. Nieva
Keyword(s):  

2014 ◽  
Vol 111 (9) ◽  
pp. 3425-3430 ◽  
Author(s):  
Julien Roche ◽  
John M. Louis ◽  
Alexander Grishaev ◽  
Jinfa Ying ◽  
Adriaan Bax

2015 ◽  
Vol 89 (23) ◽  
pp. 12189-12210 ◽  
Author(s):  
Rajesh P. Ringe ◽  
Anila Yasmeen ◽  
Gabriel Ozorowski ◽  
Eden P. Go ◽  
Laura K. Pritchard ◽  
...  

ABSTRACTWe have investigated factors that influence the production of native-like soluble, recombinant trimers based on theenvgenes of two isolates of human immunodeficiency virus type 1 (HIV-1), specifically 92UG037.8 (clade A) and CZA97.012 (clade C). When the recombinant trimers based on theenvgenes of isolates 92UG037.8 and CZA97.012 were made according to the SOSIP.664 design and purified by affinity chromatography using broadly neutralizing antibodies (bNAbs) against quaternary epitopes (PGT145 and PGT151, respectively), the resulting trimers are highly stable and they are fully native-like when visualized by negative-stain electron microscopy. They also have a native-like (i.e., abundant) oligomannose glycan composition and display multiple bNAb epitopes while occluding those for nonneutralizing antibodies. In contrast, uncleaved, histidine-tagged Foldon (Fd) domain-containing gp140 proteins (gp140UNC-Fd-His), based on the sameenvgenes, very rarely form native-like trimers, a finding that is consistent with their antigenic and biophysical properties and glycan composition. The addition of a 20-residue flexible linker (FL20) between the gp120 and gp41 ectodomain (gp41ECTO) subunits to make the uncleaved 92UG037.8 gp140-FL20 construct is not sufficient to create a native-like trimer, but a small percentage of native-like trimers were produced when an I559P substitution in gp41ECTOwas also present. The further addition of a disulfide bond (SOS) to link the gp120 and gp41 subunits in the uncleaved gp140-FL20-SOSIP protein increases native-like trimer formation to ∼20 to 30%. Analysis of the disulfide bond content shows that misfolded gp120 subunits are abundant in uncleaved CZA97.012 gp140UNC-Fd-His proteins but very rare in native-like trimer populations. The design and stabilization method and the purification strategy are, therefore, all important influences on the quality of trimeric Env proteins and hence their suitability as vaccine components.IMPORTANCESoluble, recombinant multimeric proteins based on the HIV-1envgene are current candidate immunogens for vaccine trials in humans. These proteins are generally designed to mimic the native trimeric envelope glycoprotein (Env) that is the target of virus-neutralizing antibodies on the surfaces of virions. The underlying hypothesis is that an Env-mimetic protein may be able to induce antibodies that can neutralize the virus broadly and potently enough for a vaccine to be protective. Multiple different designs for Env-mimetic trimers have been put forth. Here, we used the CZA97.012 and 92UG037.8envgenes to compare some of these designs and determine which ones best mimic virus-associated Env trimers. We conclude that the most widely used versions of CZA97.012 and 92UG037.8 oligomeric Env proteins do not resemble the trimeric Env glycoprotein on HIV-1 viruses, which has implications for the design and interpretation of ongoing or proposed clinical trials of these proteins.


1998 ◽  
Vol 95 (16) ◽  
pp. 9134-9139 ◽  
Author(s):  
Vladimir N. Malashkevich ◽  
David C. Chan ◽  
Christine T. Chutkowski ◽  
Peter S. Kim

The gp41 subunit of the envelope protein complex from human and simian immunodeficiency viruses (HIV and SIV) mediates membrane fusion during viral entry. The crystal structure of the HIV-1 gp41 ectodomain core in its proposed fusion-active state is a six-helix bundle. Here we have reconstituted the core of the SIV gp41 ectodomain with two synthetic peptides called SIV N36 and SIV C34, which form a highly helical trimer of heterodimers. The 2.2 Å resolution crystal structure of this SIV N36/C34 complex is very similar to the analogous structure in HIV-1 gp41. In both structures, three N36 helices form a central trimeric coiled coil. Three C34 helices pack in an antiparallel orientation into highly conserved, hydrophobic grooves along the surface of this coiled coil. The conserved nature of the N36-C34 interface suggests that the HIV-1 and SIV peptides are functionally interchangeable. Indeed, a heterotypic complex between HIV-1 N36 and SIV C34 peptides is highly helical and stable. Moreover, as with HIV-1 C34, the SIV C34 peptide is a potent inhibitor of HIV-1 infection. These results identify conserved packing interactions between the N and C helices of gp41 and have implications for the development of C peptide analogs with broad inhibitory activity.


2015 ◽  
Vol 61 (3-4) ◽  
pp. 235-248 ◽  
Author(s):  
Julien Roche ◽  
John M. Louis ◽  
Annie Aniana ◽  
Rodolfo Ghirlando ◽  
Ad Bax

1997 ◽  
Vol 94 (12) ◽  
pp. 6065-6069 ◽  
Author(s):  
W. Weissenhorn ◽  
L. J. Calder ◽  
A. Dessen ◽  
T. Laue ◽  
J. J. Skehel ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rute Marcelino ◽  
Filipa Gramacho ◽  
Francisco Martin ◽  
Pedro Brogueira ◽  
Nuno Janeiro ◽  
...  

AbstractThe ectodomain of gp41 is the target of potent binding and neutralizing antibodies (NAbs) and is being explored in new strategies for antibody-based HIV vaccines. Previous studies have suggested that the W164A-3S (3S) and EC26-2A4 (EC26) peptides located in the gp41 ectodomain may be potential HIV vaccine candidates. We assessed 3S- and EC26-specific binding antibody responses and related neutralizing activity in a large panel of chronic HIV-1-infected Portuguese individuals on ART. A similar proportion of participants had antibodies binding to 3S (9.6%) and EC26 (9.9%) peptides but the level of reactivity against 3S was significantly higher compared to EC26, except in the rare patients with double peptide reactivity. The higher antigenicity of 3S was unrelated with disease stage, as assessed by CD4+ T cell counts, but it was directly related with plasma viral load. Most patients that were tested (89.9%, N = 268) showed tier 1 neutralizing activity, the potency being inversely associated with plasma viral load. In the subset of patients that were tested for neutralization of tier 2 isolates, neutralization breadth was inversely correlated with plasma viral load and directly correlated with CD4+ T cell counts. These results are consistent with a role for neutralizing antibodies in controlling viral replication and preventing the decline of CD4+ T lymphocytes. Importantly, in patients with 3S-specific antibodies, neutralizing titers were inversely correlated with viral RNA levels and proviral DNA levels. Moreover, patients with 3S and/or EC26-specific antibodies showed a 1.9-fold higher tier 2 neutralization score than patients without antibodies suggesting that 3S and/or EC26-specific antibodies contribute to neutralization breadth and potency in HIV-1 infected patients. Overall, these results suggest that antibodies targeting the S3 and EC26 epitopes may contribute to reduce viral burden and provide further support for the inclusion of 3S and EC26 epitopes in HIV-1 vaccine candidates.


Sign in / Sign up

Export Citation Format

Share Document